Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%. Shake bottle before use. Wash hands after applying product. Not for oral, ophthalmic or intravaginal use. Do not use on face, ...

Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%. <12yrs: not established. Apply to affected areas once daily for up to 4 weeks; discontinue when control is achieved. 12–17yrs: ...

Allegan-based Perrigo Co. (Nasdaq: PRGO) announced that it has filed an Abbreviated New Drug Application with the United States Food and Drug Administration for calcipotriene 0.005% and betamethasone ...

LEO Pharma Inc. Announced New Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients Ages ...

What is topical calcipotriene/betamethasone used for? Topical calcipotriene/betamethasone is a combination medication commonly used to treat plaque psoriasis of the ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, makers of the Taclonex® brand of products, is offering a Patient Assistance Program designed to ...

PRINCETON, N.J. — Sandoz on Tuesday announced the U.S. market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex Ointment.

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has initiated market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex® Ointment ...

Danish drugmaker LEO Pharma has won US approval for Taclonex, a topical treatment for psoriasis that will be sold in the USA by partner Warner Chilcott. Danish drugmaker LEO Pharma has won US approval ...

ALLEGAN, Mich. — Generic drug maker Perrigo has filed for approval of a drug to treat psoriasis with the Food and Drug Administration. Perrigo announced Tuesday that it had filed an application with ...